← Human Trials & Peer-Reviewed Studies
B-type natriuretic peptide infusions in acute myocardial infarction
Plain-language guide to PMID 17639095 (2008): double-blind randomized controlled trial of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 28 patients.
Key Facts
- PMID
- 17639095
- Journal
- Heart (British Cardiac Society)
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Hillock RJ et al. (6 authors)
- DOI
- 10.1136/hrt.2006.110239
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.
To determine the utility of BNP in acute myocardial infarction (MI).
Why It Was Studied
Natriuretic peptides have actions likely to ameliorate cardiac dysfunction.
B-type natriuretic peptide (BNP) is indicated as treatment for decompensated cardiac failure.
Who Took Part
According to the abstract, 28 patients were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
28 patients with acute MI with delayed or failed reperfusion and moderate left ventricular dysfunction.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the BNP (Nesiritide) group a baseline to be compared against.
Tertiary hospital coronary care unit.
What Was Measured
The subject headings attached to it are Atrial Natriuretic Factor, Coronary Artery Disease, Cyclic GMP, Echocardiography, Doppler, Pulsed, Kidney, Myocardial Infarction and Natriuretic Agents.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) and ANP (Atrial Natriuretic Peptide) in 28 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (Heart (British Cardiac Society)), a journal based in England.
More context: the BNP (Nesiritide) compound page and the ANP (Atrial Natriuretic Peptide) compound page, all human trials.
Our Notes on the Compounds
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
ANP (Atrial Natriuretic Peptide): A 28-amino-acid heart hormone that relaxes blood vessels and increases salt excretion; carperitide is a recombinant form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.